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Abstract: Galectins (S-type lectins) are an evolutionarily-conserved family of lectin molecules,
which can be expressed intracellularly and in the extracellular matrix, as well. Galectins bind
β-galactose-containing glycoconjugates and are functionally active in converting glycan-related
information into cell biological programs. Altered glycosylation notably occurring in cancer cells and
expression of specific galectins provide, indeed, a fashionable mechanism of molecular interactions
able to regulate several tumor relevant functions, among which are cell adhesion and migration, cell
differentiation, gene transcription and RNA splicing, cell cycle and apoptosis. Furthermore, several
galectin molecules also play a role in regulating the immune response. These functions are strongly
dependent on the cell context, in which specific galectins and related glyco-ligands are expressed.
Thyroid cancer likely represents the paradigmatic tumor model in which experimental studies on
galectins’ glycobiology, in particular on galectin-3 expression and function, contributed greatly
to the improvement of cancer diagnosis. The discovery of a restricted expression of galectin-3 in
well-differentiated thyroid carcinomas (WDTC), compared to normal and benign thyroid conditions,
contributed also to promoting preclinical studies aimed at exploring new strategies for imaging
thyroid cancer in vivo based on galectin-3 immuno-targeting. Results derived from these recent
experimental studies promise a further improvement of both thyroid cancer diagnosis and therapy
in the near future. In this review, the biological role of galectin-3 expression in thyroid cancer,
the validation and translation to a clinical setting of a galectin-3 test method for the preoperative
characterization of thyroid nodules and a galectin-3-based immuno-positron emission tomography
(immuno-PET) imaging of thyroid cancer in vivo are presented and discussed.
Keywords: galectin-3; thyroid cancer; thyroid FNA-cytology, tumor imaging in vivo; immuno-PET
1. The Clinical Problem of the Preoperative Characterization of Follicular Thyroid Nodules
It has been estimated that as many as 5–6% of the adult population in the USA (about 15 million
people) have clinically-evident thyroid nodules, but this number is much higher (up to 65%) if
sub-clinical nodules incidentally discovered during a thyroid echo-scan are also counted [1,2].
Distinguishing among benign and malignant thyroid nodules is a challenge. In fact, it is very difficult
to detect preoperatively a relatively rare thyroid cancer (about 12–15% of total thyroid nodules) among
a multitude of benign thyroid nodules [3–12]. The wide use of thyroid fine-needle-aspiration (FNA)
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cytology contributed to improving the preoperative characterization of thyroid nodules, allowing
a better surgical selection of these lesions and increasing, at the same time, the number of thyroid
cancers diagnosed at histology.
Thyroid FNA cytology was first proposed at Radiumhemmet, Karolinska Hospital, Solna
(Sweden), during the year 1950 with the main purpose of distinguishing preoperatively among benign
and malignant thyroid proliferations. The first report was published in Acta Medica Scandinava in
1952 [13]. Actually, thyroid FNA cytology is widely accepted as the most effective procedure for
the preoperative diagnosis of thyroid cancer. However, since the first experience with the method,
two major limitations were observed: the first is linked to the adequacy of the sampling, although
it can be presently improved by performing FNA with an ultrasonographic guidance; the second
limitation, which occurs in 15–30% of the cases (depending on the diagnostic thyroid center considered),
represents, instead, an intrinsic limit of thyroid-cytology in providing a correct morphological diagnosis
of benign (hyperplasia and adenoma) and malignant follicular thyroid lesions (follicular carcinoma,
oncocytic follicular carcinoma and follicular variant of papillary carcinoma). This task is practically
impossible on cytological bases alone due to the overlapping cyto-morphological features in benign and
malignant follicular thyroid lesions [14–22]. In particular, the diagnosis of follicular carcinoma requires
unequivocal demonstration of capsular and/or vascular invasion. These specific morphological
hallmarks cannot be observed on cytological bases (Figure 1).
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Figure 1. Follicular thyroid lesions and galectin-3 expression on histological samples. (A) Histological 
features of follicular carcinoma showing capsular and vascular infiltration. (B) This features cannot 
be detected on cytological bases. Fine-needle-aspiration-derived thyrocytes arranged in follicular 
structures remain indeterminate (defined as category Thy-3f according to the British Thyroid 
Association). (C) Galectin-3 expression on a histological sample of the follicular variant of papillary 
thyroid carcinoma. (D) Galectin-3 expression on follicular thyroid carcinoma with capsular 
infiltration. Magnification: (A) ×200; (B–D) ×250. (A,B) Conventional haematoxylin/eosin staining; 
(C,D) direct immunoperoxidase staining by using a horseradish-peroxidase-conjugated (HRP) 
monoclonal antibody to galectin-3. 
Follicular thyroid nodules at conventional FNA cytology remain, indeed, indeterminate and are 
classified as Thy-3 according to the British Thyroid Association, or Diagnostic Category III: 
AUS/FLUS (atypia of undetermined significance/follicular lesion of undetermined significance) 
according to the Bethesda System for thyroid cytology classification [23,24]. As a consequence, 
patients bearing cytologically-indeterminate follicular nodules are frequently referred to surgery for 
a partial or complete thyroidectomy, more for diagnosis rather than for a real therapeutic necessity. 
As expected, 85–90% of these lesions will be classified as benign at the final histology, and a large 
proportion of patients will be over-treated [3,15–17,25–28]. 
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Figure 1. Follicular thyroid lesions and galectin-3 expression on histological samples. (A) Histological
features of follicular carcinoma showing capsular and vascular infiltration. (B) This features cannot
be detected on cytological bases. Fine-needle-aspiration-derived thyrocytes arranged in follicular
structures remain indeterminate (defined as category Thy-3f according to the British Thyroid
Association). (C) Galectin-3 expression on a histological sample of the follicular variant of papillary
thyroid carcinoma. (D) Galectin-3 expression on follicular thyroid carcinoma with capsular infiltration.
Magnification: (A) ×200; (B–D) ×250. (A,B) Conventional haematoxylin/eosin staining; (C,D) direct
immunoperoxidase staining by using a horseradish-peroxidase-conjugated (HRP) monoclonal antibody
to galectin-3.
Follicular thyroid nodules at convent onal FNA cytology remain, indeed, indeterminate and
are classified as Thy-3 according to the British Thyroid Associati n, or Diagnostic Category III:
AUS/FLUS (atypia of un etermined significance/follicular lesion of undetermined significance)
according to the Bethesda System for thyroid cytology classification [23,24]. As a consequence, patients
bearing cytologically-indeterminate follicular nodules are frequently referred to surgery for a partial or
complete thyroidectomy, more for diagnosis rather than for a real therapeutic necessity. As expected,
85–90% of these lesions will be classified as benign at the final histology, and a large proportion of
patients will be over-treated [3,15–17,25–28].
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Although the current clinical management of patients with thyroid nodules seems to be
“methodologically efficient”, considering the relatively low incidence of thyroid cancer and its low
mortality rate, the surgical overtreatment of such a large number of patients with benign nodules
represents a social problem. In Germany, for example, a country with a high prevalence of follicular
thyroid nodules, around 100,000 thyroid surgical procedures for benign thyroid lesions are registered
each year [29]. The large majority of these lesions are likely benign follicular nodules that were not
fully-characterized preoperatively.
In addition to the relevant costs for the public health system and patients’ distress, people
undergoing surgery for thyroid nodules have a low, but significant risk of permanent injury of the
parathyroid glands and recurrent nerves. Life-long substitutive thyroid hormone therapy is always
necessary, and calcium supplementation may be also required for patients with impaired (iatrogenic)
parathyroid function.
In the last two decades, many efforts have been directed toward developing new potential
diagnostic tools for improving thyroid cancer diagnosis preoperatively, and galectin-3 is probably one
of the most extensively-studied marker so far. The expression analysis of galectin-3 in thyroid lesions,
applied preoperatively for improving the diagnostic performance of conventional FNA cytology, has
been finally validated for translation to the clinical setting. Two large multi-institutional studies
performed at the international level and involving university hospitals and specialized thyroid centers
contributed to this achievement [30,31]. Since the year 1995 when a preliminary report on galectin-3
and thyroid cancer was published [32], despite a great variance in the methodology used, more than
300 papers published in the English literature confirmed the restricted expression of galectin-3 in
thyroid cancer, compared to normal and benign thyroid conditions [33–41]. Moreover, an independent
study of the largest thyroid cancer diagnostic marker panel reported to date showed that galectin-3 was
the most accurate stand-alone marker for well-differentiated thyroid cancer, compared to 56 different
candidate molecules [42,43]. Altogether, these data strongly support the potential role of galectin-3 as
a reliable diagnostic marker for thyroid cancer diagnosis.
2. The Biological Rationale of Galectin-3 Expression in Transformed Thyroid Cells
Galectin-3 is almost invariably expressed in well-differentiated thyroid carcinomas and can
be promptly detected in the cytoplasm of malignant thyroid cells by using immunohistochemical
procedures. On the other side, galectin-3 is undetectable in the cytoplasm of normal thyroid
follicular cells. This diagnostically-relevant finding has been extensively confirmed in the literature in
experimental tumor models in vitro, as well as on cyto-histological substrates ex vivo [30–43].
By using an in vitro model of normal thyroid cells named TAD-2, Takenaka et al. demonstrated
that a forced expression of galectin-3 via cDNA transfection induced a transformed phenotype [44].
Stable galectin-3-positive TAD-2 transfectants, in fact, acquired the phenotype of serum-independent
growth, clonogenicity in soft agar and loss of contact inhibition. Moreover, a gene expression profile
performed on galectin-3 transfectants revealed activation of genes involved in tumor growth and
progression, among which were PCNA (proliferating cell nuclear antigen), replication factor C and Rb
retinoblastoma gene. The latter’s protein product plays a significant role in G1–S transition. Conversely,
in a different set of experiments, which used a thyroid cancer and a breast carcinoma cell line, inhibition
of galectin-3 expression by using mRNA interference reverted the transformed phenotype [45,46].
These experimental findings clearly demonstrate that galectin-3 likely plays a relevant biological
role in thyroid cancer. The aberrant expression of galectin-3 in normal thyroid cells, in fact, blocks the
apoptotic program, allowing accumulation of DNA mutations and molecular alterations, which in
turn promote the development of cancer.
The galectin-3 COOH-terminal domain contains an NWGR amino acid motif highly conserved
in the BH1 domain of the Bcl-2 family of anti-apoptotic molecules. The NWGR amino acid sequence
is critical for regulating apoptosis as demonstrated by experimental studies in vitro, which used cell
transfectants carrying glycine to alanine substitution in the NWGR motif, exposed to cis-platinum
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(CDDP), a potent anticancer compound that produces an interstrand DNA cross-link and induces
apoptosis. Galectin-3 mutant transfectants in the NWGR motif showed high sensitivity to CDDP
exposure in vitro compared to the control cell lines expressing wild-type galectin-3 that remain
largely viable [47]. More recently, it has been reported that galectin-3 is a physiological target of
p53 transcriptional activity. A p53-dependent down-regulation of galectin-3 expression, occurring
at transcriptional level, is required for triggering the p53-mediated apoptotic program in different
cell systems [48]. This means that following DNA damage, wild-type p53 does not work properly in
activating the apoptotic program in a cell context in which galectin-3 remains upregulated. Indeed,
in well-differentiated thyroid carcinoma (WDTC) that notably express wt-p53, an unexplained
paradoxical concomitant expression of galectin-3 seems to occur. Interestingly, a loss of p53 activator
HIPK2 (homeodomain interacting protein kinase-2), a critical molecule that is necessary for p53
phosphorylation on serine 46, has been finally demonstrated in WDTC and was found responsible for
p53 loss of function, galectin-3 overexpression and block of apoptosis [49]. In line with these findings,
genetic studies also show that a hypomethylation state of 5 CpG sites in the galectin-3 gene correlated
with thyroid malignancies [50].
All together, these findings provide a strong biological rationale for the restricted expression of
galectin-3 in malignant thyroid cells compared to normal and benign thyroid conditions. Furthermore,
a plethora of experimental data published in the literature definitively demonstrates that WDTC
almost invariably expresses galectin-3, while normal thyroid tissue, follicular nodular hyperplasia
(multinodular goiters) and the large majority of thyroid follicular adenomas do not [33–43,51].
3. Validation of a Galectin-3 Test Method for Clinical Use
With this biological background, the potential diagnostic value of galectin-3 expression analysis
in distinguishing among benign and malignant thyroid nodules has been deeply investigated in a
large retrospective international multicenter study, which included institutions from Italy, Sweden,
the United States and Japan [30]. In this study, as many as 1006 retrospective and histologically
well-characterized thyroid lesions were independently analyzed at the immunohistochemical level
for galectin-3 expression. The analysis used a purified and well-characterized mAb to galectin-3.
Sensitivity, specificity, positive predictive value and diagnostic accuracy of galectin-3 expression in
distinguishing among benign and malignant thyroid lesions were 99%, 98%, 91% and 97%, respectively,
demonstrating that galectin-3 expression analysis is a potent and reliable diagnostic tool for thyroid
cancer detection ex vivo [30].
A galectin-3 test-method optimized for clinical use was applied, indeed, on cytological substrates
in a prospective large multicenter study, which involved 11 thyroid institutions and cancer centers.
In this study, carried out on 466 patients bearing Thy-3 follicular thyroid proliferations as candidates
for surgery, galectin-3 expression analysis was applied preoperatively on FNA-derived cellblock
preparations by using immunocyto-histochemistry [31].
The final centralized histological characterization of the resected follicular thyroid lesions
performed in blind by two independent and eminent pathologists confirmed that galectin-3 expression
analysis is an inexpensive and useful diagnostic tool, which can be easily used in clinical practice
for improving the diagnostic performance of conventional thyroid FNA cytology. The sensitivity
and specificity of the test-method applied preoperatively were 78% and 93%, respectively. Most
importantly, 88% of the Thy-3 follicular thyroid proliferations referred for surgery were correctly
classified preoperatively by using the galectin-3 test method alone [31].
Results of these studies are very exciting from the clinical point of view, considering the fact
that the correct preoperative application of the test method allows one to avoid up to 71% of
unnecessary thyroid surgical procedures, in a clinical scenario in which almost all of the follicular
thyroid proliferations (with indeterminate cytology) are still referred for surgery. Moreover, when
the galectin-3 test method is correctly used in a clinical-pathological multidisciplinary context its
diagnostic performance is further improved [52].
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Presently, an optimized galectin-3 test method for cyto-histological use has been translated to the
clinical setting and is routinely used in many thyroid institutions worldwide (Figure 2) [53].
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Figure 2. Cellblocks’ preparations from thyroid FNA cytology stained with an HRP-conjugated
mAb to galectin-3. Benign follicular thyroid proliferations do not express galectin-3: (A) follicular
adenoma; (B) nodular hyperplasia (gal-3-positive scattered foamy macrophages serve as the internal
positive control). Thyroid malignancies expressing galectin-3: (C) papillary carcinoma follicular variant;
(D) follicular carcinoma; (A–D) direct immunoperoxidase staining by using an HRP-conjugated mAb
to gal-3. Magnification: ×250.
Since the year 2003, galectin-3 expression analysis has been mentioned in the American Thyroid
Association Guidelines for the clinical management of thyroid nodules [54] and more recently in the
revised work [55]. As highlighted by Trimboli et al. in their contribution to this special issue [56],
the galectin-3 test method performs better on histological substrates compared to FNA-derived
cytological preparations. This is clearly expected if we consider the diagnostic and technical
variability that typically affects cytology and immunocytochemistry. In our experience, there is still
space for improving FNA-derived cytological preparations, immunocyto-histochemical staining and
interpretation of galectin-3 results on FNA-derived thyroid cellblocks. Basic technical and operative
guidelines for the optimal diagnostic performance of the galectin-3 test method have been published
in order to avoid the occurrence of false negative and false positive results [54]. The most important
technical r quirements for a reliable galectin-3 test method are summarized in Table 1.
When galectin-3 expression analysis is used for diagnostic purposes, the specific demonstration
of galectin-3 accumulation in the cytoplasm of transformed follicular thyroid cells is imperative,
independently of the presence or not of positive nuclear staining. This finding is biologically relevant
because it is the accumulation of galectin-3 in the cytoplasm that triggers the anti-apoptotic function.
With this in mind, we can write with confidence that a correct and reliable biological characterization
of a thyroid lesion always requires a combined morphological and immuno-phenotypical approach.
For this reason, galectin-3 expression analysis does not replace the conventional thyroid FNA cytology,
but integrates this method, with the final result of a consistent improvement of the diagnostic
performance [31].
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Table 1. Technical requirements for galectin-3 expression analysis to be applied on
fine-needle-aspiration-derived thyroid cells and conventional histological substrates.
A: A purified and well-characterized mAb to human galectin-3 (concentration ranging from 5–10 µg/mL)
must be used in immunohisto-cytochemistry (direct or indirect immunoperoxidase) with a biotin-free
detection system.
B: Galectin-3 immunostaining must be applied on formalin-fixed and paraffin embedded cyto-histological
substrates (i.e., FNA-derived cellblocks).
C: Antigen retrieval microwave treatment with 0.01 M citrate buffer, pH6 for three cycles of 3–5 min each at
750 W is necessary.
D: Follicular thyroid cells showing galectin-3 accumulation in the cytoplasm, with or without nuclear staining,
are considered positive. Scattered foamy macrophages serve as the internal positive control.
E: In Hashimoto’s thyroiditis (HT) and less frequently in chronic lymphocytic thyroiditis, false positive
immunostaining for galectin-3 may occur in follicular thyroid cells within inflammatory follicles. This may
generate false positive results (nodular lesions in HT always require a multidisciplinary clinical-pathological
evaluation for a better therapeutic decision).
F: The surgical option for galectin-3-positive cases is advisable, also in the presence of a few galectin-3-positive
thyroid follicular cells (cytoplasm +).
(Modified from Bartolazzi et al. [53].)
The clinical problem of the preoperative characterization of thyroid nodules is a challenge,
and since the publication of the first multicenter study in which galectin-3 expression analysis was
applied on thyroid histological samples [30], several molecular approaches including gene expression
profile [57] and mutational analysis [58] were also proposed for resolving this important clinical
problem. Recently, a comprehensive comparative study on the diagnostic performance, feasibility and
cost effectiveness of several diagnostic test methods, including the molecular methods proposed for
thyroid cancer diagnosis, has been published [59].
Surprisingly galectin-3 expression analysis applied at the immunocyto-histochemical level on
paraffin-embedded cyto-histological substrates showed a better diagnostic performance compared to
the GEC and Afirma molecular tests. Galectin-3 serves well both as an efficient rule-out and rule-in
test method, with a good likelihood ratio and diagnostic accuracy. Furthermore, and very importantly,
galectin-3 expression analysis does not require centralization in a single specialized laboratory, but can
be easily performed in each conventional laboratory of histology [59].
At this point, objective considerations concerning the cost of these diagnostic test methods are
also necessary. The cost of galectin-3 immunohistochemical analysis is about 113 US Dollars/test and
indeed is very competitive if compared with the cost estimated for the molecular genetic tests (20-times
more expensive). For this reason, the galectin-3 test-method has a potential screening role [58].
Considering the prevalence of indeterminate thyroid nodules at conventional cytology (about
15–30% of FNA specimens), the cost savings offered by a galectin-3-based immunocyto-histological
assay would result in being significant for both low income countries and industrialized countries
where specialized thyroid hospitals examine thousands of patients per year.
4. Thyroid Cancer Imaging In Vivo by Targeting Galectin-3
As previously mentioned, the high prevalence of benign thyroid nodules in the adult population
and the relatively rare occurrence of thyroid cancer make the preoperative identification of malignant
nodules very difficult. Several imaging approaches are currently used in clinical practice with the
attempt to detect thyroid cancer, but unfortunately, these methods are not specific enough.
Thyroid scintigraphy with radioiodine, for example, is widely used preoperatively in patients
with one or more thyroid nodules. The method provides functional information on iodine uptake (cold
or hot nodules), but it fails to distinguish among benign and malignant thyroid nodules.
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On the other side, positron emission tomography (PET) in combination with different PET tracers
like [18F]-2-fluoro-2-deoxy-D-glucose (18F-FDG), 18F-DOPA and 68Ga-somatostatin analogues has been
also used for the same purpose [60]. In particular 18F-FDG PET has been proposed as a preoperative
diagnostic procedure for detecting thyroid cancer. Although a cancer diagnosis is generally ruled
out in the presence of negative 18F-FDG PET, the sensitivity and specificity of the method are not
optimal [61–63]. Considering the plethora of data derived by the extensive analysis of galectin-3
expression in normal, benign and malignant thyroid tissue and the aforementioned biological rationale
of galectin-3 expression in transformed thyroid cells, the idea to image thyroid cancer in vivo by
targeting galectin-3 seems to be promising, coherent and clinically relevant.
Our group first proposed a novel approach for imaging thyroid cancer in vivo based on galectin-3
immunotargeting [64]. A preliminary set of experiments was performed on human thyroid cancer cell
lines xenografted in a murine experimental model. A galectin-3-based thyroid immunoscintigraphy,
which used as tracer a 99mTc-labeled mAb to galectin-3 and as detector a prototype of a mini-γ camera
for small animal imaging, was used ad hoc for imaging thyroid cancer xenografts in vivo. Results
from this preliminary study showed a good and reliable imaging of galectin-3-positive thyroid tumors
between 6 and 9 h from injection of 100 µCi of radiotracer in the tail vein, opening a new avenue in
thyroid cancer diagnosis [64]. These preliminary results clearly show the real possibility of detecting
thyroid cancer in vivo by targeting galectin-3.
Recently, a galectin-3-based immuno-positron emission tomography (immuno-PET) for imaging
thyroid cancer in vivo has been developed and used in preclinical experimental models of thyroid
cancer xenografts. The method used a thyroid cancer-specific probe obtained by radiolabeling a
purified and well-characterized mAb to galectin-3 amino-terminal epitope, with the long half-life
positron emitter zirconium-89 (89Zr; t1/2 = 74.8 h, β+ = 22.6%). Xenografted athymic Nude-Foxn1nu/nu
mice received 1.5 MBq (40 µCi) of 89Zr-labeled mAb to gal-3 in the tail vein and were subjected to
imaging sessions at 48 h post-injection.
Static PET/computer tomography (PET/CT) images showed high tumor binding specificity of
the radiotracer and a reliable imaging of thyroid cancer in vivo [64] (Figure 3).
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Figure 3. In vivo immuno-positron emission tomography (immuno-PET) imaging of thyroid tumor
by targeting galectin-3. (A) Maximum intensity projection (MIP) of µ-PET images acquired at
48 h post-injection of 40 µCi of radiotracer showing accumulation of 89Zr-labelled mAb to gal-3 in
subcutaneous tumor growing in the right thigh. 3D volume rendering (3D VR), based on CT acquisition
performed using OsiriX Image Software 5.0 (Pixmeo, Geneva, Switzerland), allows a tri-dimensional
rec nstructi n of the anatomy of the mouse and visualization of the tumor shape. The ctivity in the
liver is due t residualization of antibody metabolites. (B) A strong reduction f uptake is visualized in
mice pre-injected with 100-fold excess of unlabeled mAb to gal-3 and imaged 48 h post-injection of
the radiotracer, confirming the binding specificity. Normal thyroid gland does not express detectable
galectin-3, and as expected, no accumulation of the radiotracer was visible in the neck region.
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The reliability of the proposed imaging approach has been confirmed in three different animal
models of human thyroid cancer xenografts including a follicular carcinoma and a poorly-differentiated
thyroid carcinoma.
The specificity of galectin-3 immuno-PET targeting for imaging thyroid cancer has been further
confirmed by an extensive ex vivo biodistribution analysis, measuring the amount of 89Zr-labeled
probe accumulated in tumors and normal tissues explanted from the experimental animals [65].
Concluding, galectin-3 immuno-PET targeting represents a new potential diagnostic method for
in vivo detection and biological characterization of thyroid nodules, which deserves to be further
improved for clinical translation. Preclinical studies on orthotopic models of thyroid cancer are ongoing
to confirm the preliminary findings. Galectin-3 immuno-PET strategy for imaging thyroid cancer
in vivo is supported by a strong clinical and biological rationale and has the potential to improve, in
the near future, the clinical management of patients bearing thyroid nodules, reducing unnecessary
surgery and social costs [66–68].
Galectin-3 immuno-PET may potentially improve thyroid cancer diagnosis in the following
conditions: (a) in the presence of multiple thyroid nodules, which cannot be easily analyzed
preoperatively by using conventional FNA cytology; (b) in the presence of small suspicious
sub-centimetric lesions (3–4 mm) discovered in a deep mediastinal position or intimately associated
with vascular structures, for which fine-needle-aspiration-biopsy evaluation can be difficult or harmful;
(c) the method may be also applied to distinguish among thyroid cancer infiltration/residual tumor
nests and minimal normal thyroid tissue residues after thyroid surgery. This represents a common
clinical problem during follow-up of patients after a thyroid cancer surgery. Although many of
these conditions are presently detected with radioiodine, they remain largely uncharacterized at
biological level.
(d) Moreover, a fraction of poorly-differentiated thyroid carcinomas and anaplastic thyroid
carcinomas (rare lesions) generally express galectin-3, but lose the ability to uptake radioiodine.
In these specific cases, immuno-PET targeting of galectin-3 might be useful for detecting residual
disease and to provide information for a better clinical management and therapeutic intervention of
each specific case.
Although the preclinical experimental work performed with galectin-3 immuno-PET has been
focused on thyroid cancer detection in vivo, the proposed technology could be useful in different tumor
conditions. Galectin-3, in fact, is expressed in different primary and metastatic tumors (i.e., melanoma,
breast carcinoma, prostatic carcinoma) [51]. The possibility to image these tumors in vivo or to
detect metastasis (i.e., metastatic sentinel lymph nodes) represents an interesting field of research to
be investigated.
At least theoretically, increasing the LET (linear energy transfer) of the radionuclide linked to
the galectin-3-specific probe will generate a tool for immuno-radiotherapy and/or radio-ablation of
the so-called “occult thyroid carcinomas” of millimetric dimension. These lesions are generally
undetectable preoperatively. Further, preclinical studies in the field are ongoing, as well as
humanization of galectin-3-specific mAbs and/or adequate structural modifications of these probes
(i.e., the creation of radiolabeled F(ab)-fragments or chimeric molecules). This work will be necessary
for translating the method to the clinical setting.
5. Conclusions
In the present Special Issue of the International Journal of Molecular Sciences focused on galectins
in cancer and translational medicine, other experiences with galectin-1, galectin-3 and thyroid cancer
are reported by different research groups [56,69]. Very interestingly, some papers published in this
issue also show the possibility to inhibit specific galectins in vivo by using both natural and synthetic
inhibitors [70]. We are confident that research in glycobiology of galectins will contribute in the
near future to improve both cancer diagnosis and treatment of several tumor conditions, discovering
targetable galectin-mediated functions that are critical for cancer [51,71].
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Concluding: i) glycobiology of galectin-3; ii) the biological effects induced by galectin-3 in tumor
cells in vitro; iii) the extensive characterization of galectin-3 expression performed on human thyroid
tissues ex vivo; iv) the possibility to imaging thyroid cancer in vivo by using a galectin-3 immuno-PET
represent all together a fashionable journey from the bench to the bed-side, which has already provided
important improvements in clinical practice.
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